VETOQUINOL Corporate brochure 2010 (year 2009)

GROWTH ACTIVITY REPORT 2009 03 2009 WAS A RATHER ENCOURAGING YEAR; WE WEATHERED THE CRISIS AND SUCCEEDED IN BUILDING STRONG EXTERNAL GROWTH. In so doing, we are taking a significant market position in Asia, a region with very high growth potential. The Indian operations that we acquired are perfectly in line with our strategy, which is to remain focused on our areas of expertise and our specialities. Indeed, we are concentrating on a part of the market, with two aims: to be a key player in the livestock field and for the most common companion animals, i. e. dogs and cats, and to be able to focus on our three therapeutic areas (anti-infectives, pain-inflammation and cardiology-nephrology). AFTER 46 YEARS AT THE HEAD OF THE COMPANY FOUNDED BY YOUR FATHER, YOU ARE HANDING OVER TO YOUR SON, MATTHIEU. HOW DOES EACH OF YOU SEE THE FUTURE OF VÉTOQUINOL? Étienne Frechin • I have always wanted to find a successor among my children and am very happy that Matthieu has agreed to succeed me. He has all the capabilities required to assume the position of CEO, and this handover is a guarantee of continuity and independence for our customers and shareholders. Matthieu Frechin • In the coming years, the difference will hinge on marketing skills. No doubt the competitive challenges will demand decisions that are slightly different and bolder. I intend to uphold our specific values, which are based on innovation and the ability to promote the advantages of our products. My priorities are to continue optimising our production facilities and to further develop our brand with products that are at the forefront of research, whilst remaining ready to seize development opportunities in the mature markets that are Europe and America, as well as in major emerging markets.